

Stella (1836 HK)

A dividend play riding on the athleisure trend

We think the risk-reward currently for Stella is excellent, because of: 1) a turnaround of the clothing and sportswear sector in the US, 2) the company's specific strengths like its high-end positioning (e.g. producing Jordan series for Nike) and ramp-up of footwear business by luxury brands (acquired 17-18 new clients, like Moncler, Lacoste and Kenzo (under LVMH) in the past two years) and 3) undemanding valuation of 8x FY23E P/E and 9% FY23E yield.

■ **Company-wise, we expect Stella's growth to accelerate and outperform its peers.** We are impressed that Stella not only managed to resume positive sales growth of 13% in 4Q23, but also outperformed peers like Feng Tay (-3%), Eclat (+10%) and Makalot (+9%). Referring to our NDR call recently, management is still confident on accelerated growth in FY24E (low-teen net profit growth, with 0% to MSD volume and flattish ASP growth), even after a beat in FY23E results. In our view, the general picture in FY24E and FY25E is: 1) sportswear companies to shift from de-stocking to re-stocking, 2) luxury brand sales growth to be soft but price hikes shall continue, and 3) high-end fashion and casual names' growth to slowly pick up but with healthy discounts and inventory levels. **And we think Stella can further differentiate itself and deliver an outstanding result, thanks to:**

1) Stella's high-end positioning (it is the maker of Jordan athleisure series, as well as many other limited or cross-over collections) and its strategic partnership with Nike. Therefore, it should be able to recover faster during the Nike's turnaround (from de-stocking in FY23E to re-stocking in FY24E), and the U-rate of sports segment factory should increase gradually (80%+ in FY24E and 90%+ in FY25E (close to pre-Covid level). During FY19-23, Jordan brand sales growth was always faster than Nike group's. Moreover, the construction of a new factory (with designed capacity of 10mn pairs of shoes) in Indonesia for Nike (to be opened in early FY26E) is still on track.

2) The popular trend of category expansion by the luxury and high-end fashion brands. Many brands are looking for new growth drivers and category expansion is one of that. In fact, we can tell from the sales mix of the Prada and Gucci brands that their footwear sales were all climbing from FY19 to 9M23. Therefore, as one of the best high-end athleisure shoes maker in town, we are confident that Stella can ramp this up further. In the past two years, it has acquired about 17 to 18 clients (e.g. Moncler, Lacoste, Kenzo (under the LVMH group)), and these could provide a boost in orders in FY25E (as the product testing usually last for around 1-2 years for a new client). For example, one of Moncler's lately strategy is to generate around 10% of sales from its footwear business in the mid-term.

Earnings Summary

(YE 31 Dec)	FY18A	FY19A	FY20A	FY21A	FY22A
Revenue (RMB mn)	1,589	1,545	1,136	1,541	1,631
YoY growth (%)	0.7	-2.8	-26.5	35.6	5.9
Net income (RMB mn)	62	96	1	91	117
EPS (RMB)	0.08	0.12	0.00	0.11	0.15
YoY growth (%)		54.1	-98.9	8,446.0	29.0
Consensus EPS (RMB)	N/A	N/A	N/A	N/A	N/A
P/E (x)	14.3	13.6	553.4	10.7	6.3
P/B (x)	1.0	1.3	1.0	1.0	0.8
Yield (%)	6.5	6.8	5.0	2.2	13.3
ROE (%)	6.8	10.0	0.2	9.3	11.8
Net gearing (%)	Net cash	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIGM estimates

NOT - RATED

Current Price

HK\$10.46

China Textile Sector

Walter Woo

(852) 3761 8776

walterwoo@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	8,318
Avg 3 mths t/o (HK\$ mn)	5.25
52w High/Low (HK\$)	10.76/7.10
Total Issued Shares (mn)	795.2

Source: Bloomberg

Shareholding Structure

Cordwalner Bonaventure Inc.	21.85%
Mr. Chiang Jeh-Chung	6.43%
Mr. Chen Li-Ming	3.62%
Free Float	68.10%


Source: HKEx, Bloomberg

Share Performance

	Absolute	Relative
1-mth	16.2%	23.2%
3-mth	21.7%	31.7%
6-mth	40.6%	74.2%
12-mth	35.3%	90.9%

Source: Bloomberg

12-mth Price Performance




Source: Bloomberg

Auditor: Ernst & Young

- **We tend to believe the US retail sales growth (so as the subsectors like clothing and sportswear) has started to turnaround, despite various uncertainties.** Firstly, US retail trade sales growth already accelerated to 3.1% in both Nov and Dec 2023, from 1.6% in Oct and 2.0% in 3Q23. The pattern is similar to the clothing and sportswear sub-sectors (picked up from -1.4%/ -2.4% in Oct 2023 to 2.8%/ 0.3% in Nov-Dec 2023). Secondly, the inventory level peaked out as well, and sales to inventory ratio for the clothing sector dropped from 2.4x in Dec 2022, to 2.37x in Sep 2023 and 2.34x in Dec 2023. Thirdly, the outlook for 2024 should be at least better than that in 2023. According to a survey done by BoF-Mckinsey State of Fashion, about 26% and 37% of the fashion industry executives found 2024 better or the same vs 2023, improving from 16% and 28% back in the 2023 survey. And this background has echoed with Stella's outperformance in Dec 2023, where some of its luxury and high-end fashion clients experienced strong sell-through and ordered early shipments for the items planned for Jan 2024.
- **We are confident on its 3-year target and even beyond.** Currently, Stella has three new factories in the pipeline, where the designed capacity are 10mn pairs in Indonesia (started in FY23E), 5mn pairs in Bangladesh (will start in FY24E) and another 10mn pairs in Indonesia (will start in FY26E). Therefore by FY27E, the total designed capacity can be as high as 85mn pairs a year, implying a MSD to HSD volume CAGR during FY23E-27E. Supported by Stella's leadership in R&D and product quality, we are optimistic about the ramp-up and shift of segment mix (where the optimistic level should be 40%-45% for luxury and high-end fashion, 45% for sports and 10%-15% for casual). Together with various measures to lift efficiency (e.g. merging the R&D centres for luxury, high-end fashion and casual) and shift of casual segment orders from Vietnam to Indonesia and Bangladesh), we do find the 3-year target (10% OP margin and low-teen net profit growth during FY23E-25E) totally achievable.
- **Stella is a world-class athleisure shoes maker.** Stella is a leading developer and manufacturer of high-end footwear and leather goods. It has over 50 clients while the major ones are Nike, Deckers, Cole Haan, Balenciaga, Michael Kors, Timberland, Tory Burch, etc. It is also an exporter with over 75% sales going into the US and EU in FY22 while its production bases are spread across China (~25%), Vietnam (~50%) and the rest of Asia. While Huali and Feng Tay are also focusing on footwear manufacturing for similar clients, Stella is mainly making and selling athleisure shoes (such Nike's Jordan's retro series, Balenciaga's Triple S series) and lady shoes (e.g. UGG's classic), which are different from those more functional and performance-based sneakers.
- **The risk-reward is still attractive.** Thanks to the highly attractive dividend yield of 9% FY23E and 11% FY24E yield, we see the downside protected. And with undemanding P/E of 8x FY23E and 7x FY24E, plus the low-teens NP growth, we think the upside is huge.


Focus charts

Figure 1: US retail trade sales growth (YoY)




Source: US Census Bureau, CMBIGM estimates

Figure 2: US clothing and sports related retail sales growth (YoY)




Source: US Census Bureau, CMBIGM estimates

Figure 3: US clothing sector's sales to inventory ratio



Source: US Census Bureau, CMBIGM estimates


Figure 4: Nike's inventory and growth (YoY)




Source: Company data, CMBIGM estimates

Figure 5: Expectations for 2024, by fashion industry executives


Expectations for how fashion industry conditions will evolve in the year ahead compared to prior year,
% of respondents




Source: BoF-McKinsey State of Fashion 2024 Executive Survey, CMBIGM

Figure 6: Quarterly sales growth (YoY), by Stella and its peers


Source: Company data, CMBIGM estimates

Figure 7: Nike sales growth (YoY)


Source: Company data, CMBIGM estimates

Figure 8: Sales growth (YoY) of Nike brand, Jordan brand and Stella's sales (to Nike)

Source: Company data, CMBIGM estimates

Figure 9: Prada's sales mix, by product segment

Source: Company data, CMBIGM estimates

Figure 10: Gucci's sales mix, by product segment

Source: Company data, CMBIGM estimates

Figure 11: Moncler's footwear segment's mid-term target (10% of total sales)

...Supported by a new FOOTWEAR offer from outdoor to city luxury

Out Lux
Luxury Outdoor Redefined



DNA inspired, Functional and Innovative Outdoor Footwear. Quality & Durability

Street Lux
Utilitarian take on athletic sneakers



A beautiful blend between traditional aesthetics, Footwear and Moncler's DNA

Hybrid Lux
The future of footwear, now



Moncler's hub for endless design explorations, new technologies, sustainable materials, modern shapes and colour applications

City Lux
Where Style meets Tech




High-end Italian craftsmanship combined with Moncler outdoor's DNA

FOOTWEAR EXPECTED TO REACH 10% OF REVENUES

Source: Company data, CMBIGM

Valuation

Figure 12: Forward 12M P/E valuation band



Source: Bloomberg, CMBIGM estimates

Valuation

Figure 13: Peers valuation table

Company	Ticker	Rating	12m TP (LC)	Price (LC)	Up/Down-side	Mkt. Cap (HK\$mn)	Year End	P/E (x)		P/B (x)	ROE (%)	3yrs PEG (x)	Yield (%)	YTD perf.
								FY1E	FY2E	FY2E	FY0	FY1E	FY1E	FY1E
H shares Sportswear														
Stella	1836 HK	NR	n/a	10.46	n/a	8,318	Dec-22	8.0	7.1	0.4	11.3	0.6	9.2	13.6
Shenzhou	2313 HK	NR	n/a	67.95	n/a	102,144	Dec-22	20.4	16.6	2.6	14.0	1.8	2.8	(15.5)
Crystal	2232 HK	NR	n/a	2.97	n/a	8,473	Dec-22	6.4	5.8	0.7	12.8	0.9	5.0	2.4
Huali	300979 CH	NR	n/a	53.00	n/a	67,350	Dec-22	19.6	16.6	3.5	22.7	2.5	2.1	0.7
Yue Yuen	551 HK	NR	n/a	7.62	n/a	12,285	Dec-22	8.3	5.7	0.4	5.0	4.6	8.5	(11.8)
Regina Miracle	2199 HK	NR	n/a	2.01	n/a	2,461	Mar-23	8.0	6.2	0.6	5.3	0.7	3.7	(6.5)
Pacific Textiles	1382 HK	NR	n/a	1.24	n/a	1,735	Mar-23	6.5	5.9	0.6	4.7	0.7	13.7	(8.1)
Nameson	1982 HK	NR	n/a	0.50	n/a	1,140	Mar-23	n/a	n/a	n/a	7.5	n/a	n/a	0.0
Best Pacific	2111 HK	NR	n/a	1.09	n/a	1,133	Dec-22	4.0	3.0	0.3	8.7	0.3	10.1	(1.8)
Feng Tay	9910 TT	NR	n/a	161.50	n/a	40,030	Dec-23	21.4	18.2	5.2	22.7	n/a	3.2	(7.7)
Eclat	1476 TT	NR	n/a	547.00	n/a	37,671	Dec-22	28.5	23.4	5.3	18.6	30.0	2.6	(2.7)
Makalot	1477 TT	NR	n/a	357.50	n/a	21,703	Dec-22	21.8	19.3	5.1	25.8	2.3	4.0	0.8
Avg.								13.9	11.6	2.2	13.3	4.5	5.9	(3.1)
Med.								8.3	7.1	0.7	12.1	1.4	4.0	(2.2)

Source: Bloomberg, CMBIGM estimates

Note: Data as of 30 Jan 2024.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.